Infliximab and the TNF-alpha system.

Infliximab, a chimeric monoclonal antibody against TNF-alpha, is efficacious in Crohn's disease (CD) and rheumatoid arthritis (RA). Its main mechanism of action is thought to be the induction of apoptosis. The present study evaluates in detail the effects of infliximab on the TNF-alpha system using peripheral blood monocytes and T cells as well as lamina propria lymphocytes from normal individuals and patients with CD, ulcerative colitis, and RA. Lymphocytes were studied in the resting state in the absence of strong stimuli that may obscure subtle findings. Infliximab did not change the numbers of viable cells. Rather, it caused monocytes to increase their release of soluble TNFR2, which serves to neutralize TNF-alpha, potentiating the action of infliximab. It reduced TNFR2 expression, thereby decreasing TNF-alpha responsiveness. These changes were due to upregulated production of TNFR2 rather than increased shedding. Infliximab did not cause rebound production of TNF-alpha transcripts that would counteract its effects. It specifically enhanced production of IL-10 but not proinflammatory cytokines secreted by leukocytes, thereby promoting an anti-inflammatory microenvironment. In addition, infliximab caused a rise in c-Jun amino-terminal kinase phosphorylation by monocytes. Thus infliximab manipulates the TNF-alpha system to promote its anti-TNF-alpha effects.

[1]  T. Horiuchi,et al.  Membrane Tumor Necrosis Factor-α (TNF-α) Expressed on HTLV-I-Infected T Cells Mediates a Costimulatory Signal for B Cell Activation—Characterization of Membrane TNF-α , 1997 .

[2]  S. Targan,et al.  Differential p38 Mitogen-Activated Protein Kinase Target Phosphorylation in Responders and Nonresponders to Infliximab , 2003 .

[3]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[4]  J. Dahlerup,et al.  Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[5]  G. Corazza,et al.  Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease , 2003, Gut.

[6]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[7]  B. Scallon,et al.  Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .

[8]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[9]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[10]  E. Ebert,et al.  Intestinal intraepithelial lymphocytes have a promiscuous interleukin-8 receptor. , 1997, Gut.

[11]  B. Aggarwal,et al.  TNF induces internalization of the p60 receptor and shedding of the p80 receptor. , 1994, Journal of immunology.

[12]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[13]  E. Ebert.  CD2 activation of human lamina propria lymphocytes reduces CD3 responsiveness , 2006, Immunology.

[14]  G. Kollias,et al.  Tumor necrosis factor‐receptor 2 is up‐regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo , 2002, European journal of immunology.

[15]  C. Alessandri,et al.  Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13 , 2002, Annals of the rheumatic diseases.

[16]  P. Rutgeerts,et al.  Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[17]  K. Kaltoft,et al.  Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. , 2001, Cytokine.

[18]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[19]  F. Breedveld,et al.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.

[20]  P. Pavli,et al.  Evidence for a CD14+ population of monocytes in inflammatory bowel disease mucosa—implications for pathogenesis , 1995, Clinical and experimental immunology.

[21]  P. Rosenstiel,et al.  Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease. , 2005, Gut.

[22]  J. Belaiche,et al.  Profile of soluble cytokine receptors in Crohn’s disease , 2005, Gut.

[23]  三苫 弘喜.  Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α , 2007 .

[24]  S. Nasraway,et al.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.

[25]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[26]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[27]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[28]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[29]  T. Brunner,et al.  Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. , 2004, Gastroenterology.

[30]  P. Rutgeerts,et al.  Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept , 2005, Alimentary pharmacology & therapeutics.

[31]  P. Rutgeerts,et al.  Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. , 1999, Gastroenterology.

[32]  M. Feldmann,et al.  Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes , 1994, European journal of immunology.

[33]  J. Dahlerup,et al.  The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures , 2003 .

[34]  S. Deventer,et al.  Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease , 2002, Gut.

[35]  T. Horiuchi,et al.  Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. , 2005, Gastroenterology.

[36]  J. Silver,et al.  Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. , 2004 .

[37]  M. Pierer,et al.  Ex Vivo Homeostatic Proliferation of CD4+ T Cells in Rheumatoid Arthritis Is Dysregulated and Driven by Membrane-Anchored TNFα1 , 2004, The Journal of Immunology.

[38]  J. Woody,et al.  In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. , 1996, Journal of immunology.

[39]  Y. Saeki,et al.  Long-Term Follow-Up of the Changes in Circulating Cytokines, Soluble Cytokine Receptors, and White Blood Cell Subset Counts in Patients with Rheumatoid Arthritis (RA) After Monoclonal Anti-TNFα Antibody Therapy , 1999, Journal of Clinical Immunology.

[40]  Walter Kolch,et al.  Reverse Signaling Through Transmembrane TNF Confers Resistance to Lipopolysaccharide in Human Monocytes and Macrophages1 , 2000, The Journal of Immunology.

[41]  L. Williams,et al.  Tumor necrosis factor α‐induced activation of c‐jun N‐terminal kinase is mediated by TRAF2 , 1997, The EMBO journal.

[42]  Philip Rosenstiel,et al.  p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease1 , 2002, The Journal of Immunology.

[43]  G. Kollias,et al.  A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling , 1997, European journal of immunology.

[44]  T. Horiuchi,et al.  Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. , 2004, Gastroenterology.